Session: SAT 270-310-Thyroid Neoplasia (posters)
Poster Board SAT 300
Objectives: To evaluate the presence of CTCs in peripheral blood of patients with MPTC, we tested patients with MPTC and controls, attempting to establish a new prognostic /surrogate marker of disease progression and response to therapy. We also wished to see if the lung cancer probe set could accurately detect CTCs of MPTC.
Patients and Methods: We recruited 12 MPTC patients (aged 62±15.7 years) and 8 control patients (aged 46.9±12.1 years) with history of PTC, total thyroidectomy and disease-free (NED) for ≥5 years. Thirty healthy subjects with absence of known thyroid and lung cancer (aged 62.7±7.8 year) were included as a second control group. Peripheral blood mononuclear cells were isolated and hybridized with a multi-color cocktail of 4 DNA probes: 2 locus specific probes at 10q22 (SFTPA1, 2) and 3p22, and 2 centromeric probes, CEP10 and CEP3. A scanning system scored fluorescent signals on a per cell basis on 500 cells. Signal patterns were independently analyzed by 2 readers into distinct classes: CTCs (cells with gains of ≥2 probes), deletions or gains (loss or gain of a single probe), and normal cells.
Results: Patients with MPTC had higher CTCs (0.9±0.3, P<0.001 and 99.9% power) than patients with NED (0.18±0.18) or healthy controls (0.18±0.23). The cutoff of 0.6% CTC (3/500 cells) differentiated between MPTC and controls from both groups. Compared with healthy controls, patients with MPTC had higher percentages of deletion of CEP 3 (0.80±0.85 vs 0.19±0.53, P=0.006), CEP10 (1.43±1.37 vs 0.45±0.67, P=0.002), gain of CEP10 (0.45±0.34 vs 0.23±0.28, P=0.03) and gain of 10q22.3 (0.77±0.60 vs 0.13±0.17, P<0.001), deletions and gains (5.68±1.91 vs 2.47±1.27, P<0.001) and decreased percentage of normal cells (94.33±1.88 vs 97.52 ±1.24, P<0.00001).
Conclusion: Blood from MPTC patients demonstrated CTCs characterized by aneuploidy, with higher levels of CTCs compared with controls. The probes designed for lung cancer were successful in detecting genetic aberrations in MPTC patients’ CTCs, possibly resulting from similar lineage-specific chromosomal changes in lung and thyroid malignant progenitor cells. Studies with larger cohorts are needed to confirm the significance of CTCs as a prognostic marker for MPTC.
Nothing to Disclose: JYX, TZ, GJC, MINH, SGW, MEC, AKY, NLB, MAH, NS, DT, RKY, SS, RLK, SIS
*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting/pr-resources-for-endo
See more of: Abstracts - Orals, Poster Previews, and Posters